Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis

Yuiko Sato, Toshimi Tando, Mayu Morita, Kana Miyamoto, Tami Kobayashi, Ryuichi Watanabe, Takatsugu Oike, Morio Matsumoto, Masaya Nakamura, Takeshi Miyamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.

Original languageEnglish
Pages (from-to)1430-1436
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume482
Issue number4
DOIs
Publication statusPublished - 2017 Jan 22

Fingerprint

Selective Estrogen Receptor Modulators
Vitamin D
Osteoporosis
Bone
Bone and Bones
Tamoxifen
Androgens
Testosterone
Hormones
Orchiectomy
Bone Fractures
eldecalcitol
Prostatic Neoplasms
Therapeutics

Keywords

  • Bazedoxifene
  • Eldecalcitol
  • Male osteoporosis
  • Raloxifene
  • Selective estrogen receptor modulators
  • Tamoxifen

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis. / Sato, Yuiko; Tando, Toshimi; Morita, Mayu; Miyamoto, Kana; Kobayashi, Tami; Watanabe, Ryuichi; Oike, Takatsugu; Matsumoto, Morio; Nakamura, Masaya; Miyamoto, Takeshi.

In: Biochemical and Biophysical Research Communications, Vol. 482, No. 4, 22.01.2017, p. 1430-1436.

Research output: Contribution to journalArticle

Sato, Yuiko ; Tando, Toshimi ; Morita, Mayu ; Miyamoto, Kana ; Kobayashi, Tami ; Watanabe, Ryuichi ; Oike, Takatsugu ; Matsumoto, Morio ; Nakamura, Masaya ; Miyamoto, Takeshi. / Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 482, No. 4. pp. 1430-1436.
@article{dbdf112e981f4bd281dfb021c695a7ad,
title = "Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis",
abstract = "Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.",
keywords = "Bazedoxifene, Eldecalcitol, Male osteoporosis, Raloxifene, Selective estrogen receptor modulators, Tamoxifen",
author = "Yuiko Sato and Toshimi Tando and Mayu Morita and Kana Miyamoto and Tami Kobayashi and Ryuichi Watanabe and Takatsugu Oike and Morio Matsumoto and Masaya Nakamura and Takeshi Miyamoto",
year = "2017",
month = "1",
day = "22",
doi = "10.1016/j.bbrc.2016.12.053",
language = "English",
volume = "482",
pages = "1430--1436",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis

AU - Sato, Yuiko

AU - Tando, Toshimi

AU - Morita, Mayu

AU - Miyamoto, Kana

AU - Kobayashi, Tami

AU - Watanabe, Ryuichi

AU - Oike, Takatsugu

AU - Matsumoto, Morio

AU - Nakamura, Masaya

AU - Miyamoto, Takeshi

PY - 2017/1/22

Y1 - 2017/1/22

N2 - Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.

AB - Rapid increases in the number of elderly people have dramatically increased the number of female and male osteoporosis patients. Osteoporosis often causes bone fragility fractures, and males exhibit particularly poor prognosis after these fractures, indicating that control of osteoporosis is crucial to maintain quality of men's lives. However, osteoporosis therapies available for men have lagged behind advances available for women. Here, we show that three selective estrogen receptor modulators (SERMs), namely, raloxifene, bazedoxifene, and tamoxifen, plus the vitamin D analogue ED71, also called eldecalcitol, completely block orchiectomy-induced, testosterone-depleted bone loss in male mice in vivo. Patients treated with hormone deprivation therapy for prostate cancer also exhibit male osteoporosis, and bone management is critical for these patients. Given that androgen replacement therapy is not an option for these patients, our results represent a novel approach potentially useful to control male osteoporosis.

KW - Bazedoxifene

KW - Eldecalcitol

KW - Male osteoporosis

KW - Raloxifene

KW - Selective estrogen receptor modulators

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85028260031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028260031&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.12.053

DO - 10.1016/j.bbrc.2016.12.053

M3 - Article

C2 - 27974229

AN - SCOPUS:85028260031

VL - 482

SP - 1430

EP - 1436

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -